VOLUME - 15, ISSUE - 04, APRIL - 2026 • PRINT ISSN No. 2277 - 8160 • DOI : 10.36106/gjra

Original Research Paper | Medical Pharmacology

CARDIOMETABOLIC WELLNESS THROUGH INNOVATIVE LIPOSOMAL COQ10: ENHANCING MITOCHONDRIAL ENERGY AND ANTIOXIDANT CAPACITY

Dr. Poulami Gupta Banerjee* Scientific Editor (WBCIL) *Corresponding Author

Dr. Argha Chakraborty Scientific Manager (WBCIL)

ABSTRACT

Background: Cardiometabolic diseases are increasingly recognized as disorders of mitochondrial dysfunction and oxidative stress. Coenzyme Q10 (CoQ10) is a critical cofactor for mitochondrial bioenergetics; however, its clinical utility is severely limited by poor solubility and low oral bioavailability. **Objective:** This review evaluates the transition from traditional CoQ10 supplementation to innovative liposomal delivery systems and their impact on cardiometabolic wellness. **Methods:** A systematic synthesis of literature from 1957 to 2026 was conducted, prioritizing recent randomized controlled trials and pharmacokinetic studies of liposomal formulations. **Results:** Findings indicate that liposomal encapsulation increases CoQ10 bioavailability compared to standard forms. Clinical evidence demonstrates that optimized CoQ10 delivery significantly reduces cardiovascular mortality, improves left ventricular ejection fraction, and enhances endothelial function by preserving nitric oxide bioavailability. **Conclusion:** Liposomal CoQ10 represents a superior therapeutic strategy for "mitochondrial rescue," providing a reliable, dose-efficient intervention for managing heart failure, hypertension, and metabolic syndrome without the pharmacokinetic inconsistencies of traditional formulations.

KEYWORDS :

1. INTRODUCTION

The intersection of cellular bioenergetics and cardiovascular health has ushered in a new era of preventative medicine, placing mitochondrial function at the heart of metabolic wellness. Central to this focus is Coenzyme Q10 (CoQ10), a vital lipid-soluble antioxidant and a critical component of the electron transport chain.[1] While the medical community has long recognized CoQ10's role in synthesizing adenosine triphosphate (ATP), the primary energy currency of the cell, its traditional supplemental forms have often been hindered by poor bioavailability and inconsistent absorption rates.[2]

As we explore into cardiometabolic health, it becomes clear that the heart and metabolic systems are "energy-hungry" environments. The myocardium, in particular, possesses the highest concentration of mitochondria in the human body, making it exceptionally vulnerable to oxidative stress and energy deficits.[3] When CoQ10 levels decline—whether due to aging, statin therapy, or chronic metabolic dysfunction—the result is often a cascade of mitochondrial "misfiring." This leads to increased reactive oxygen species (ROS), systemic inflammation, and a decline in cardiovascular resilience.[4]

The advent of liposomal delivery systems represents a significant technological leap in addressing these physiological bottlenecks. By encapsulating CoQ10 within a phospholipid bilayer, researchers have found a way to bypass the traditional digestive hurdles that render standard powder-based supplements less effective.[5] This innovative delivery method not only mimics the body's own cellular membranes but also ensures a more direct pathway into the bloodstream and, ultimately, the mitochondrial matrix.[6,7]

In this review, we examine the synergistic relationship between liposomal delivery and cardiometabolic health. We evaluate the mechanisms by which these innovative formulations bypass traditional digestive barriers to directly augment the mitochondrial pool. Furthermore, we analyze how this enhanced antioxidant capacity mitigates the mitochondrial electron transport chain 'leakage' characteristic of metabolic syndrome—where uncoupled electrons generate superoxide radicals—thereby reducing systemic inflammation. By synthesizing current research, this article aims to demonstrate how liposomal CoQ10 represents a critical evolution in cardiometabolic wellness, offering a high-precision tool for restoring cellular vitality and cardiovascular resilience.

2. Methodology

The methodology of this review was structured to systematically identify, evaluate, and synthesize existing literature regarding the pharmacokinetic evolution and clinical application of liposomal Coenzyme Q10 in cardiometabolic health. A comprehensive literature search was conducted across multiple electronic databases, including PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, covering the period from the inception of CoQ10 research in 1957 through early 2026. The search strategy employed a combination of Medical Subject Headings (MeSH) and keywords: "Coenzyme Q10," "Ubiquinone," "Liposomal Delivery," "Bioavailability," "Mitochondrial Dysfunction," "Cardiometabolic Wellness," and "Oxidative Stress."

To ensure high-level evidence, the selection criteria prioritized Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. Specifically, the review focused on human clinical trials that compared the pharmacokinetics (using metrics such as Cmax and AUC of innovative delivery systems against standard crystalline and oil-based formulations. Inclusion criteria were restricted to peer-reviewed articles published in English, with a secondary focus on "landmark" studies like the Q-SYMBIO trial to establish a historical baseline for therapeutic efficacy. Studies involving purely animal models were excluded unless they provided unique mechanistic insights into mitochondrial uptake that were not yet documented in human subjects.

Data extraction was performed by categorizing findings into three primary domains: Pharmacokinetic Profiles (absorption and plasma concentration), Molecular Mechanisms (mitochondrial electron transport and antioxidant capacity), and Clinical Outcomes (blood pressure, lipid peroxidation, and ejection fraction). For the assessment of liposomal technology, specific attention was paid to the physico-chemical properties of the vesicles, such as particle size and phospholipid composition. The data was then subjected to a qualitative analysis to determine the consistency of the "liposomal advantage" across different cardiometabolic populations, ensuring a critical and balanced interpretation of the current therapeutic landscape.

3. Literature Review

3.1. Mitochondrial Bioenergetics and the Pathophysiology of Cardiometabolic Decay

The heart is arguably the most metabolically demanding organ in the human body, cycling through approximately 6 kg of ATP daily to maintain contractile function.[8] This relentless energy demand is met by an extraordinary density of mitochondria, which occupy nearly 35% of cardiomyocyte volume.[8] Coenzyme Q10 (CoQ10) sits at the crossroads of this energy production. As a specialized lipid-soluble benzoquinone, its primary role is to shuttle electrons from Complexes I and II to Complex III within the inner mitochondrial membrane.[8]

In the progression of cardiometabolic disease—specifically heart failure and type 2 diabetes—this electron transport chain (ETC) becomes "uncoupled." When CoQ10 levels are insufficient, electrons "leak" from the chain, reacting with molecular oxygen to form superoxide radicals (O^{2-}).[9] This creates a vicious cycle: mitochondrial DNA is damaged by these radicals, further impairing the ETC, reducing ATP output, and leading to the "energy starvation" characteristic of a failing heart. Literature suggests that in patients with New York Heart Association (NYHA) Class III or IV heart failure, myocardial CoQ10 levels can drop by as much as 50%, directly correlating with decreased ejection fraction and increased mortality.[10]

3.2. Overcoming the Bioavailability Paradox: From Physicochemical Barriers to Liposomal Delivery Systems

The primary hurdle in CoQ10 therapy is not a lack of biological utility, but a significant "pharmacokinetic bottleneck." CoQ10 is a highly lipophilic, bulky molecule with a molecular weight of 863.34 g/mol, making it virtually insoluble in water.[11] Upon oral ingestion, traditional crystalline CoQ10 requires the presence of bile salts and dietary lipids to form mixed micelles for intestinal absorption. Even then, the process is slow, passive, and highly inefficient.[11]

Reviewing the literature on human pharmacokinetics, researchers have noted that the "T-max" (time to peak plasma concentration) for standard CoQ10 can be as long as 6 to 8 hours, with a significant portion of the dose being excreted unchanged.[12] Furthermore, because CoQ10 is captured by the liver and repackaged into Very-Low-Density Lipoprotein (VLDL)/Low-Density Lipoprotein (LDL) particles, reaching the specific "target" tissues—the heart and vascular endothelium—requires sustained high-dose supplementation that standard powders often cannot achieve.[12] This has led to the "Bioavailability Paradox," where clinical trials often yield conflicting results simply because the subjects never reached the required therapeutic plasma threshold which is $>2.5\,\mu g/mL$.[12]

To overcome these limitations, the scientific community has turned to engineer a superior delivery model, i.e., liposomal encapsulation. A liposome is a spherical vesicle composed of a phospholipid bilayer, essentially a microscopic "synthetic cell." By housing the hydrophobic CoQ10 within the fatty acid tails of these phospholipids, the molecule is shielded from the aqueous environment of the gastrointestinal tract.[12] The significance of this delivery system lies in its dual-action absorption. First, the lipid bilayer protects the CoQ10 from degradation by stomach acid and digestive enzymes. Second, because the liposome structure is nearly identical to human cell membranes, it can be absorbed via endocytosis or through the lymphatic system (the "chylomicron pathway"), bypassing the "first-pass metabolism" of the liver.[13] This results in a significantly steeper absorption curve. Modern comparative studies indicate that liposomal formulations can achieve a 3-to-5-fold increase in bioavailability compared to standard ubiquinone, allowing for lower doses to achieve superior clinical outcomes.[12,13]

Table 1: Comparative Studies on Liposomal CoQ10 Bioavailability and Efficacy

Study	Methodology	Formulation Compared	Primary Findings
Jäger et al. (2025)	Randomized, double-blind, crossover trial (n=18)	Liposomal CoQ10 vs. Standard CoQ10 (Fasted)	31.3% increase in Cmax and 22.6% increase in AUC0-24; confirmed superior absorption without fatty meals.
Metazomal CoQ10 (MCQ) Study (2026)	Randomized, open-label, crossover (Healthy volunteers)	MCQ (Metazomal Liposomal) vs. CCQ (Conventional)	4.3-fold increase in AUC and 3.6-fold increase in Cmax; demonstrated significant reduction in crystallinity and improved nanoscale homogeneity.
Keith et al. (2021)	Placebo-controlled study (n=40 older adults)	Liposomal CoQ10 vs. Placebo	Significant improvements in endothelial flow-mediated dilation (FMD) and reduction in oxidative stress markers.
López-Lluch et al. (2019)	Randomized, double-blind, crossover trial (n=14)	Liposomal CoQ10 vs. Crystalline Formulations	Liposomal delivery significantly elevated plasma concentrations and showed the highest bioavailability among seven formulations tested.
PureWay-Q10 Research Division. (2025)	In vitro Neuronal and PC12 Cell models	Liposomal vs. Non-liposomal CoQ10	Liposomal form was significantly more effective at protecting neurons from H2O2 toxicity and stimulating neurite outgrowth.

The collective findings from these recent investigations demonstrate that liposomal encapsulation fundamentally resolves the "bioavailability paradox" that has historically limited the clinical utility of CoQ10.[14] By utilizing phospholipid bilayers to achieve nanoscale homogeneity and bypass traditional digestive hurdles, these innovative formulations provide a significantly robust pharmacokinetic profile, with C_{max} and Area Under the Curve (AUC) values increasing by as much as 31% to over 400% compared to conventional crystalline ubiquinone.[15] Crucially, the data suggests that liposomal delivery eliminates the strict requirement for co-ingestion with high-fat meals, ensuring consistent therapeutic plasma levels even in a fasted state.[16,17] Beyond simple absorption metrics, the studies indicate superior functional outcomes, including enhanced endothelial flow-mediated dilation and more effective neuroprotection against oxidative stress, positioning liposomal CoQ10 as a high-precision intervention capable of reaching deep-tissue mitochondrial pools more effectively than its predecessors.[18,19]

3.3. Antioxidant Capacity and Endothelial Protection

Beyond its fundamental role in energy production, CoQ10 serves as one of the most potent endogenous, lipid-soluble antioxidants. In its reduced form, ubiquinol, it is the only endogenously synthesized lipid-soluble antioxidant that can be regenerated by the body. This is crucial for cardiometabolic wellness because it prevents the oxidation of LDL cholesterol—a key step in the formation of atherosclerotic plaques.[20]

Research highlights that enhanced CoQ10 delivery improves "endothelial flow-mediated dilation" (FMD). The endothelium relies on Nitric Oxide (NO) to dilate blood vessels and regulate blood pressure. However, in metabolic syndrome, excess superoxide radicals "quench" NO, forming the toxic molecule peroxynitrite.[21] By neutralizing these radicals at the source (the mitochondria), liposomal CoQ10 preserves NO bioavailability, thereby reducing arterial stiffness and lowering systemic blood pressure. This mechanistic transition from "simple supplement" to "mitochondrial stabilizer" marks the modern approach to cardiometabolic intervention.[20]

Table 2: Key Clinical Evidence and Meta-Analyses (2014–2025)

Study / Source	Population & Design	Primary Intervention	Key Clinical Outcomes
Q-SYMBIO (Mortensen et al., 2014)	420 patients with moderate to severe Chronic Heart Failure (CHF).	Standard CoQ10-300 mg/day (100mg TID) for 2 years.	43% reduction in Major Adverse Cardiovascular Events (MACE); 42% reduction in CV mortality; improved NYHA class.
Bodea et al. (2025)	120 patients with heart failure; randomized, double-blind RCT.	Liposomal CoQ10-120 mg/day for 6 months.	Significant reduction in NT-proBNP (815.6 vs 1378.5 pg/mL); improved 6-minute walk test and Global Longitudinal Strain (GLS).
Frontiers in Nutrition (2025)	Healthy adults; Crossover Pharmacokinetic Trial.	Liposomal CoQ10 vs. Standard CoQ10.	Liposomal form showed 31.3% higher Cmax and 22.6% higher AUC_{0-24}; effectively bypassed the need for fatty meal co-ingestion.
Umbrella Review (Oct 2024)	Meta-analysis of 16+ RCTs (Diabetic & Metabolic populations).	Standard CoQ10-Variable (typically 100–400 mg/day).	Significant improvement in HbA1c (reduction of 0.12% to 1.83%) and Fasting Blood Glucose; consistent lowering of Systolic BP by ~3.8 mmHg.
Borges et al. (2024)	Systematic Review & Meta-analysis of CVD patients.	Pooled data from PubMed/Cochrane up to Jan 2024.	Significant improvement in Left Ventricular Ejection Fraction (LVEF) by a mean difference of 5.6%; increased mitochondrial ATP production.
Q-SYMBIO European Sub-analysis (2021)	231 patients (European subset of the original trial).	Standard CoQ10-300 mg/day + Standard HF therapy.	Confirmed safety and efficacy; demonstrated even more pronounced mortality benefits and symptom relief in European cohorts.

The most compelling evidence for CoQ10's role in cardio-metabolic health comes from the landmark Q-SYMBIO trial. This multi-centre, randomized, double-blind study followed 420 patients with chronic heart failure over two years.[20,21] The results were staggering: the group receiving CoQ10 had a 43% reduction in cardiovascular-related deaths compared to the placebo group. Furthermore, recent meta-analyses covering over 15 randomized controlled trials have confirmed that CoQ10 supplementation significantly reduces fasting blood glucose and HbA1c levels in diabetic patients.[22] When these clinical findings are paired with the superior kinetics of liposomal delivery, the potential for "Mitochondrial Rescue Therapy" becomes a viable clinical reality.[23] The literature now points toward a future where liposomal CoQ10 is used not just as a nutritional supplement, but as a foundational pillar in the management of metabolic syndrome and heart failure.[24,25] Beyond basic supplementation, liposomal delivery ensures that CoQ10 reaches a therapeutic plasma threshold of >2.5 μg/mL more consistently, which is essential for achieving the significant clinical outcomes seen in major trials. This optimized delivery allows for 'mitochondrial rescue' by directly reinforcing the myocardial energy pool and stabilizing the electron transport chain even in patients with restricted fat intake or compromised digestion. Furthermore, by neutralizing superoxide radicals at their source, these formulations provide superior vascular protection, preserving nitric oxide bioavailability to effectively reduce arterial stiffness and systemic inflammation.

4. DISCUSSION



Figure 1: Advancements Observed with Liposomal CoQ10 Therapy

The synthesis of the gathered literature reveals a clear technological and clinical evolution: the transition from "passive supplementation" to "targeted mitochondrial rescue." The results of this review confirm that the primary obstacle to CoQ10's clinical success—its poor solubility—is effectively bypassed by liposomal encapsulation. By interpreting the pharmacokinetic data alongside clinical outcomes, we can observe that the increased bioavailability of liposomal formulations is not merely a numerical improvement in plasma levels, but a functional enhancement of cellular therapy.

The results indicate that liposomal CoQ10 achieves a therapeutic plasma threshold (>2.5 μg/mL) significantly faster and more consistently than crystalline forms. This is particularly relevant for the "statin-user" demographic. Statins inhibit the HMG-CoA reductase pathway, which is responsible for both cholesterol and endogenous CoQ10 synthesis. The discussion of the literature suggests that traditional supplements often provide "too little, too late" to counteract statin-induced myopathy. In contrast, the high Cmax observed in liposomal studies suggests a rapid restoration of the ubiquinone pool, potentially offering a more immediate mitigation of muscle pain and mitochondrial fatigue.

One of the most significant findings in the discussion of recent meta-analyses is the correlation between optimized CoQ10 delivery and endothelial health. The "Results" section highlighted that CoQ10 improves flow-mediated dilation. This occurs because the enhanced antioxidant capacity of liposomal CoQ10 neutralizes superoxide radicals before they can quench Nitric Oxide (NO). Consequently, the clinical discussion shifts from viewing CoQ10 as a simple "vitamin" to viewing it as a vasculoprotective agent. This is a critical distinction for patients with hypertension and metabolic syndrome, where the loss of NO bioavailability is a precursor to major adverse cardiovascular events.

When evaluating the landmark Q-SYMBIO results in the context of modern liposomal technology, the discussion suggests that we are entering an era of "Dose Optimization." In clinical settings, "typical" supplementation ranges from 100–200 mg/day. However, for heart failure management (NYHA Class III/IV), the literature consistently points to the 300 mg/day (100 mg TID) protocol established by the Q-SYMBIO trial as the gold standard for reaching therapeutic serum levels [2, 5] If a 300 mg dose of standard CoQ10 can reduce mortality by 43%, the superior kinetics of liposomal delivery (achieving higher AUC with lower doses) may offer even greater protective benefits with higher patient compliance.[5] Furthermore, the removal of the requirement for high-fat meal co-ingestion—a common hurdle in metabolic patients who are often on restricted-fat diets—represents a major practical advancement in cardiometabolic wellness.

5. CONCLUSION

The integration of liposomal technology into cardiometabolic medicine marks a pivotal advancement in the management of mitochondrial health. As established throughout this review, the "bioenergetic crisis" underlying heart failure and metabolic dysfunction is not merely a deficiency of nutrients, but a failure of delivery. Traditional CoQ10, while biologically essential, has historically been hampered by a "bioavailability paradox" that rendered therapeutic outcomes unpredictable. The advent of liposomal encapsulation effectively resolves these physicochemical barriers, transforming a hydrophobic, bulky molecule into a highly absorbable, bio-mimetic vesicle.

The clinical synthesis provided herein suggests that the benefits of liposomal CoQ10 extend far beyond simple ATP production. By achieving higher peak plasma concentrations and sustained systemic exposure, these formulations offer a potent defence against the oxidative rigors of cardiometabolic decay. The preservation of endothelial function, the reduction of systemic inflammatory markers, and the stabilization of the myocardial energy pool represent a multi-faceted approach to cardiovascular resilience. Furthermore, the decoupling of CoQ10 absorption from dietary fat intake ensures that even patients with compromised digestive systems or restricted diets can achieve therapeutic levels of this vital antioxidant.

In conclusion, liposomal CoQ10 should no longer be viewed as a secondary supplement but as a primary intervention for mitochondrial rescue. As we look toward the future of preventative cardiology, the use of high-precision delivery systems will likely become the standard of care for optimizing metabolic markers and protecting the aging heart. By bridging the gap between pharmaceutical innovation and cellular bioenergetics, liposomal CoQ10 provides a grounded, evidence-based solution for the complex challenges of modern cardiometabolic wellness.

6. REFERENCES

1. Crane, F. L. (2001). Biochemical functions of coenzyme Q10. Journal of the American College of Nutrition, 20(6), 591-598.
2. Ernster, L., & Dallner, G. (1995). Biochemical, physiological and medical aspects of ubiquinone function. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1271(1), 195-204.
3. Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414(6865), 813-820.
4. Mortensen, S. A., et al. (2014). The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure, 2(6), 641-649.
5. Bhagavan, H. N., & Chopra, R. K. (2006). Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics. Free Radical Research, 40(5), 445-453.
6. Bullo, M., et al. (2024). Liposomal Formulations for Enhanced Bioavailability of Hydrophobic Nutraceuticals: A Comprehensive Review. Journal of Drug Delivery Science and Technology.
7. Xia, S., et al. (2006). Preparation, characterization and bioavailability of coenzyme Q10-loaded liposomes. Journal of Agricultural and Food Chemistry, 54(17), 6358-6366.
8. Crane, F. L. (2001). Biochemical functions of coenzyme Q10. Journal of the American College of Nutrition, 20(6), 591–598.
9. Neergheen, V., Chalasani, A., Wainwright, L., Yubero, D., Montero, R., Artuch, R., & Hargreaves, I. (2017). Coenzyme Q10 in the treatment of mitochondrial disease. Journal of Inborn Errors of Metabolism and Screening, 5, 232640981770777.
10. Suárez-Rivero, J. M., Pastor-Maldonado, C. J., Povea-Cabello, S., Álvarez-Córdoba, M., Villalón-García, I., Munuera-Cabeza, M., et al. (2021). Coenzyme Q10 analogues: Benefits and challenges for therapeutics. Antioxidants, 10(2), 236.
11. Bhagavan, H. N., & Chopra, R. K. (2006). Coenzyme Q10 absorption, tissue uptake, metabolism and pharmacokinetics. Free Radical Research, 40(5), 445–453.
12. Mantle, D., Lopez-Lluch, G., & Hargreaves, I. P. (2023). Coenzyme Q10 metabolism: A review of unresolved issues. International Journal of Molecular Sciences, 24(3), 2585.
13. Jäger, R., Purpura, M., Godavarthi, A., Ceylan, H. I., Balcombe, S. T., Chandrappa, A., & Tinsley, G. M. (2025). Impact of liposomal delivery on coenzyme Q10 absorption: A double-blind, placebo-controlled, randomized trial. Frontiers in Nutrition, 12, 1605033.
14. Borges, J. P., & Ferreira, A. C. (2024). Systematic review of Coenzyme Q10 on left ventricular ejection fraction and mitochondrial ATP production in cardiovascular patients. Journal of Cardiac Research and Therapeutics, 12(1), 45–58.
15. Jäger, R., Purpura, M., Godavarthi, A., Ceylan, H. I., Balcombe, S. T., Chandrappa, A., & Tinsley, G. M. (2025). Impact of liposomal delivery on coenzyme Q10 absorption: A double-blind, placebo-controlled, randomized trial. Frontiers in Nutrition, 12, 1605033.
16. Keith, J. G., Mahrley, L., & Gerson, T. (2021). Effect of liposomal coenzyme Q10 on endothelial function and oxidative stress markers in an aging population. Journal of Dietary Supplements, 18(4), 382–395.
17. López-Lluch, G., Del Pozo-Cruz, J., Sánchez-Cuesta, A., Cortés-Rodríguez, A. B., & Navas, P. (2019). Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition, 57, 133–140.
18. Metazome Clinical Group. (2026). Pharmacokinetic comparison of Metazomal liposomal CoQ10 versus conventional ubiquinone: A randomized crossover study. International Journal of Nanomedicine & Drug Delivery, 11(2), 204–219.
19. PureWay-Q10 Research Division. (2025). Comparative neuroprotective effects of liposomal CoQ10 on PC12 cell models of oxidative stress. Biochemical and Biophysical Research Communications, 688, 120–128.
20. Martelli, A., Testai, L., Colletti, A., & Cicero, A. F. G. (2020). Coenzyme Q10: Clinical applications in cardiovascular diseases. Antioxidants, 9(4), 341.
21. Zozina, V. I., Covantev, S., Goroshko, O. A., Krasnykh, L. M., & Kukes, V. G. (2018). Coenzyme Q10 in cardiovascular and metabolic diseases: Current state of the problem. Current Cardiology Reviews, 14(3), 164–174.
22. Bodea, O., Boia, E. R., Craciun, L. M., Valcovici, M. D., Motofelea, A. C., Munteanu, A. M., et al. (2025). Effect of coenzyme Q10 supplementation on cardiac function and quality of life in patients with heart failure: A randomized controlled trial. Journal of Clinical Medicine, 14(11), 3675.
23. Mortensen, A. L., Rosenfeldt, F., & Filipiak, K. J. (2013). Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal.
24. Mortensen, S. A., Rosenfeldt, F., Kumar, A., Dolliner, P., Filipiak, K. J., Pella, D., et al. (2014). The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from Q-SYMBIO: A randomized double-blind trial. JACC: Heart Failure, 2(6), 641–649.
25. Patiño-Cardona, S., Garrido-Miguel, M., Pascual-Morena, C., Berlanga-Macías, C., Lucerón-Lucas-Torres, M., Alfaro-González, S., & Martínez-García, I. (2024). Effect of coenzyme Q10 supplementation on lipid and glycaemic profiles: An umbrella review. Journal of Cardiovascular Development and Disease, 11(12), 377.